Industry news

• Fully instrumented 3D printed small-scale bioreactor developed

  23 November 2023 Catherine Eckford / European Pharmaceutical Review

  Researchers have reported on the development of a small-scale 3D printed, single-use bioreactor suitable for a broad range of mammalian and microbial cultivation. Overall, the study described in a paper published in Processes, illustrated the possibility of additive manufacturing of radiation-sterilisable, single-use bioreactors.

• EU pharma legislation key in tackling AMR

  22 November 2023 Catherine Eckford / European Pharmaceutical Review

  According to the European Federation of Pharmaceutical Industries and Associations (EFPIA), the EU general pharmaceutical legislation has potential to shape the future of EU actions against antimicrobial resistance (AMR).

• The next phase of decentralization in clinical trials

  22 November 2023 FiercePharma

  There were 250 decentralised clinical trials (DCTs) worldwide in 2012. By 2021, there were 1,291. Dan Tanner, chief commercial officer at Cerba Research, explains how the firm is helping to create a new paradigm in clinical trials.

• Working group on staffing shortage in medicine formed in the State Duma

  21 November 2023 GxPNews

  The State Duma has formed a unique working group that spans across factions. This group will focus its efforts on tackling the pressing issue of the lack of healthcare stuff. Chairman of the Committee on Health Protection Badma Bashankaev, spoke about this, clarifying that the initiative to create the group belongs to the Chairman of the State Duma Vyacheslav Volodin.

• EC approves lebrikizumab for atopic dermatitis

  21 November 2023 Catherine Eckford / European Pharmaceutical Review

  Monoclonal antibody, lebrikizumab, is approved in Europe for treatment of adults and adolescents with moderate-to-severe atopic dermatitis.

• Trial for novel CGRP migraine medicine gleans positive results

  20 November 2023 Catherine Eckford / European Pharmaceutical Review

  The first pill designed to directly block calcitonin gene-related peptide (CGRP), a protein released during a migraine attack, has demonstrated positive evidence in AbbVie’s trial investigating its efficacy in the prodrome phase.

• Pharma is racing to oncology's first line, causing a rethink of early-stage disease treatment

  20 November 2023 Annalee Armstrong / FiercePharma

  Timothy Yap, Ph.D., used to see patients nearing the end of their cancer journey in his phase 1 department at the University of Texas' MD Anderson Cancer Center. Either they fit into a phase 1 trial, or they were off to hospice for end-of-life care.

• First CRISPR-based gene-editing therapy authorised

  17 November 2023 Catherine Eckford / European Pharmaceutical Review

  The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted a world-first regulatory authorisation to a medicine based on Nobel Prize-winning technology. 

• Single-use bioprocessing market to value $84.14bn by 2032

  17 November 2023 Catherine Eckford / European Pharmaceutical Review

  In the single-use bioprocessing market, research states that automation offers benefits such as process control in biopharma manufacturing.

• Mishustin: “Genetic research must be prioritized”

  16 November 2023 GxPNews

  During a crucial conference on food security, the chairman of the government of the Russian Federation, also informally known as the prime minister, the head of government of Russia,  emphasized the urgent need to enhance breeding research and advance the development of agrobiotechnologies.